CLRB News and Press, Cellectar Biosciences Inc. From 01/09/24

2024-01-09 19:36:03 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; NexImmune Inc (NASDAQ: NEXI), Adicet Bio Inc (NASDAQ: ACET), Cellectar Biosciences Stock (NASDAQ: CLRB), and Accolade (NASDAQ: ACCD). Other than ...

2024-01-09 12:40:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cutera Inc (NASDAQ: CUTR), Sentage Holdings (NASDAQ: SNTG), NexImmune Inc (NASDAQ: NEXI), Adicet Bio In...

2024-01-09 01:05:44 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Cellectar Biosciences, Inc. (NASDAQ: CLRB), Aclarion, Inc. (NASDAQ: ACON), Ardelyx (NASDAQ: ARDX), Sidus Space Inc. (NASDAQ: SIDU), NexImmune Inc. (NASDA...

2024-01-08 12:34:45 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Aclarion Inc (NASDAQ: ACON), Spectaire Holdings Inc (NASDAQ: SPEC), Cellectar Biosciences Inc (NASDAQ: ...

2024-01-08 10:13:03 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Vincerx Pharma Inc (NASDAQ: VINC), Canoo Inc (NASDAQ: GOEV), Aclarion Inc (NASDAQ: ACON), Spectaire Holdings I...

2024-01-08 07:15:09 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...

2024-01-08 06:56:58 ET DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported, this morning, data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapy candidate for the treat...

Iopofosine tested in heavily pretreated multi-class refractory population with a median of four prior therapies and achieves 75.6% Overall Response Rate; 61% Major Response Rate ( 95% CI, 44.5%, 75.8%) ; 100% Disease Control Rate exceeding protocol statistical hurdle of 20% ...

Management to host conference call on Monday, January 8, 2024, at 8:00 am ET Company also to present at the Biotech Showcase FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on...

2023-12-26 08:22:28 ET Gainers: RayzeBio ( RYZB ) +100% on being acquired by Bristol Myers Squibb . Gracell Biotechnologies ( GRCL ) +60% to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases . IMAC Holdings ( BA...